145 related articles for article (PubMed ID: 12396831)
21. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer.
Stanislawski T; Voss RH; Lotz C; Sadovnikova E; Willemsen RA; Kuball J; Ruppert T; Bolhuis RL; Melief CJ; Huber C; Stauss HJ; Theobald M
Nat Immunol; 2001 Oct; 2(10):962-70. PubMed ID: 11577350
[TBL] [Abstract][Full Text] [Related]
22. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy.
Gribben JG; Ryan DP; Boyajian R; Urban RG; Hedley ML; Beach K; Nealon P; Matulonis U; Campos S; Gilligan TD; Richardson PG; Marshall B; Neuberg D; Nadler LM
Clin Cancer Res; 2005 Jun; 11(12):4430-6. PubMed ID: 15958627
[TBL] [Abstract][Full Text] [Related]
23. Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma.
Mizukoshi E; Nakamoto Y; Marukawa Y; Arai K; Yamashita T; Tsuji H; Kuzushima K; Takiguchi M; Kaneko S
Hepatology; 2006 Jun; 43(6):1284-94. PubMed ID: 16729333
[TBL] [Abstract][Full Text] [Related]
24. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin.
Hirohashi Y; Torigoe T; Maeda A; Nabeta Y; Kamiguchi K; Sato T; Yoda J; Ikeda H; Hirata K; Yamanaka N; Sato N
Clin Cancer Res; 2002 Jun; 8(6):1731-9. PubMed ID: 12060610
[TBL] [Abstract][Full Text] [Related]
25. [Human telomerase reverse transcriptase as a novel target for tumor immunotherapy].
Pang JX
Ai Zheng; 2003 Aug; 22(8):893-5. PubMed ID: 12917043
[TBL] [Abstract][Full Text] [Related]
26. Uses of telomerase peptides in anti-tumor immune therapy.
Li H; Katik I; Liu JP
Methods Mol Biol; 2007; 405():61-86. PubMed ID: 18369818
[TBL] [Abstract][Full Text] [Related]
27. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients.
Andersen MH; Pedersen LO; Capeller B; Bröcker EB; Becker JC; thor Straten P
Cancer Res; 2001 Aug; 61(16):5964-8. PubMed ID: 11507035
[TBL] [Abstract][Full Text] [Related]
28. Isolation and characterization of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic subunit.
Lev A; Denkberg G; Cohen CJ; Tzukerman M; Skorecki KL; Chames P; Hoogenboom HR; Reiter Y
Cancer Res; 2002 Jun; 62(11):3184-94. PubMed ID: 12036932
[TBL] [Abstract][Full Text] [Related]
29. Prospects and challenges of building a cancer vaccine targeting telomerase.
Vonderheide RH
Biochimie; 2008 Jan; 90(1):173-80. PubMed ID: 17716803
[TBL] [Abstract][Full Text] [Related]
30. In vitro generated cytolytic T lymphocytes reactive against head and neck cancer recognize multiple epitopes presented by HLA-A2, including peptides derived from the p53 and MDM-2 proteins.
Asai T; Storkus WJ; Mueller-Berghaus J; Knapp W; DeLeo AB; Chikamatsu K; Whiteside TL
Cancer Immun; 2002 Apr; 2():3. PubMed ID: 12747748
[TBL] [Abstract][Full Text] [Related]
31. The universal character of the tumor-associated antigen survivin.
Andersen MH; Svane IM; Becker JC; Straten PT
Clin Cancer Res; 2007 Oct; 13(20):5991-4. PubMed ID: 17947459
[TBL] [Abstract][Full Text] [Related]
32. Survivin as an immunotherapeutic target for adult and pediatric malignant brain tumors.
Liu R; Mitchell DA
Cancer Immunol Immunother; 2010 Feb; 59(2):183-93. PubMed ID: 19756596
[No Abstract] [Full Text] [Related]
33. Mapping and binding analysis of peptides derived from the tumor-associated antigen survivin for eight HLA alleles.
Bachinsky MM; Guillen DE; Patel SR; Singleton J; Chen C; Soltis DA; Tussey LG
Cancer Immun; 2005 Mar; 5():6. PubMed ID: 15779886
[TBL] [Abstract][Full Text] [Related]
34. Sequential administration of the native TERT572 cryptic peptide enhances the immune response initiated by its optimized variant TERT(572Y) in cancer patients.
Vetsika EK; Papadimitraki E; Aggouraki D; Konsolakis G; Mela ME; Kotsakis A; Christou S; Patramani S; Alefantinou M; Kaskara A; Christophyllakis C; Kosmatopoulos K; Georgoulias V; Mavroudis D
J Immunother; 2011; 34(9):641-50. PubMed ID: 21989412
[TBL] [Abstract][Full Text] [Related]
35. Tumour immunotherapy: new tools, new treatment modalities and new T-cell antigens.
Schultze JL; Maecker B; von Bergwelt-Baildon MS; Anderson KS; Vonderheide RH
Vox Sang; 2001 Feb; 80(2):81-9. PubMed ID: 11378969
[TBL] [Abstract][Full Text] [Related]
36. Universal tumor antigens for cancer vaccination: targeting telomerase for immunoprevention.
Vonderheide RH
Discov Med; 2007 Aug; 7(39):103-8. PubMed ID: 18093471
[TBL] [Abstract][Full Text] [Related]
37. A general strategy to optimize immunogenicity of HLA-B*0702 restricted cryptic peptides from tumor associated antigens: Design of universal neo-antigen like tumor vaccines for HLA-B*0702 positive patients.
Gallou C; Rougeot A; Graff-Dubois S; Kosmatopoulos K; Menez-Jamet J
Oncotarget; 2016 Sep; 7(37):59417-59428. PubMed ID: 27506946
[TBL] [Abstract][Full Text] [Related]
38. The repertoire of human tumor-associated epitopes--identification and selection of antigens and their application in clinical trials.
Haen SP; Rammensee HG
Curr Opin Immunol; 2013 Apr; 25(2):277-83. PubMed ID: 23619309
[TBL] [Abstract][Full Text] [Related]
39. Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes.
Cohen CJ; Gartner JJ; Horovitz-Fried M; Shamalov K; Trebska-McGowan K; Bliskovsky VV; Parkhurst MR; Ankri C; Prickett TD; Crystal JS; Li YF; El-Gamil M; Rosenberg SA; Robbins PF
J Clin Invest; 2015 Oct; 125(10):3981-91. PubMed ID: 26389673
[TBL] [Abstract][Full Text] [Related]
40. Potential target antigens for a universal vaccine in epithelial ovarian cancer.
Vermeij R; Daemen T; de Bock GH; de Graeff P; Leffers N; Lambeck A; ten Hoor KA; Hollema H; van der Zee AG; Nijman HW
Clin Dev Immunol; 2010; 2010():. PubMed ID: 20885926
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]